Literature DB >> 10770911

Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.

J E Kaplan1, D Hanson, M S Dworkin, T Frederick, J Bertolli, M L Lindegren, S Holmberg, J L Jones.   

Abstract

The incidence of nearly all AIDS-defining opportunistic infections (OIs) decreased significantly in the United States during 1992-1998; decreases in the most common OIs (Pneumocystis carinii pneumonia ¿PCP, esophageal candidiasis, and disseminated Mycobacterium avium complex ¿MAC disease) were more pronounced in 1996-1998, during which time highly active antiretroviral therapy (HAART) was introduced into medical care. Those OIs that continue to occur do so at low CD4+ T lymphocyte counts, and persons whose CD4+ counts have increased in response to HAART are at low risk for OIs, a circumstance that suggests a high degree of immune reconstitution associated with HAART. PCP, the most common serious OI, continues to occur primarily in persons not previously receiving medical care. The most profound effect on survival of patients with AIDS is conferred by HAART, but specific OI prevention measures (prophylaxis against PCP and MAC and vaccination against Streptococcus pneumoniae) are associated with a survival benefit, even when they coincide with the administration of HAART. Continued monitoring of incidence trends and detection of new syndromes associated with HAART are important priorities in the HAART era.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770911     DOI: 10.1086/313843

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  181 in total

Review 1.  Mechanisms of fungal resistance: an overview.

Authors:  Maher M Balkis; Steven D Leidich; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates.

Authors:  P Richard Harrigan; Brendan A Larder
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

3.  Immune Reconstitution Strategies in HIV.

Authors:  Matthew R. Leibowitz; Ronald T. Mitsuyasu
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

Review 4.  Life and death in a macrophage: role of the glyoxylate cycle in virulence.

Authors:  Michael C Lorenz; Gerald R Fink
Journal:  Eukaryot Cell       Date:  2002-10

5.  Causes of hospitalization and perceived access to care among persons newly diagnosed with HIV infection: implications for HIV testing programs.

Authors:  Lokesh Shahani; Christine Hartman; Cathy Troisi; Asha Kapadia; Thomas P Giordano
Journal:  AIDS Patient Care STDS       Date:  2011-12-07       Impact factor: 5.078

6.  Emerging opportunistic fungal infections: where are we heading?

Authors:  Vincent Idemyor
Journal:  J Natl Med Assoc       Date:  2003-12       Impact factor: 1.798

Review 7.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

Review 8.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Evaluation of a Turbidimetric β-d-Glucan Test for Detection of Pneumocystis jirovecii Pneumonia.

Authors:  Karl Dichtl; Ulrich Seybold; Johannes Wagener
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

10.  HIV infection and microbial diversity in saliva.

Authors:  Yihong Li; Deepak Saxena; Zhou Chen; Gaoxia Liu; Willam R Abrams; Joan A Phelan; Robert G Norman; Gene S Fisch; Patricia M Corby; Floyd Dewhirst; Bruce J Paster; Alexis S Kokaras; Daniel Malamud
Journal:  J Clin Microbiol       Date:  2014-02-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.